PREJUDICE to the BRAZIL PHARMA reaches R $ 39 MILLION

The company closed the fourth quarter of 2013 with adjusted net loss of $ 39,890 million compared with profit of $ 8,847 million in the same period the previous year. According to the company, the result was adjusted to expunge the effect of expenditure/income and non-recurring costs, expenses with PCOS (stock option plan) and the effect of amortization of intangible assets (commercials). Without the adjustments, the damage reached r $ 188,246 million, against r $ 12,272 million negatives recorded between October and December 2012. The company's net operating revenue grew up 13.73% over the period to R $ 893,717 million.